Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints (RESYNC-PACE)

8. července 2026 aktualizováno: Peter Ezer, University of Pecs

REstoration of SYNChronous Cardiac Function Due to Physiologic cArdiac Pacing Modalities With Clinical Endpoints RESYNC-PACE

The goal of this observational study is to evaluate the long-term clinical outcomes of physiologic cardiac resynchronization therapy (CRT) using conduction system pacing strategies compared with conventional biventricular CRT in patients with heart failure with reduced ejection fraction (HFrEF) and electrical dyssynchrony.

The main questions it aims to answer are:

  • Does physiologic CRT (including left bundle branch area pacing [LBBAP] and LBBAP-optimized CRT) reduce the combined risk of all-cause mortality and heart failure hospitalization compared with conventional biventricular CRT?
  • Does physiologic CRT improve cardiac function and reverse ventricular remodeling more effectively than conventional CRT?

Participants receiving physiologic CRT as part of routine clinical care will undergo standard follow-up evaluations, including electrocardiography, echocardiography, laboratory testing, and device interrogation. Clinical outcomes will be collected prospectively for 24 months and compared with a historical cohort of patients treated with conventional biventricular CRT.

The study will assess clinical outcomes, echocardiographic response, electrical resynchronization parameters, and device-related safety in a real-world heart failure population.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Background

Heart failure with reduced ejection fraction (HFrEF) is associated with substantial morbidity, mortality, and healthcare utilization despite continuous advances in guideline-directed medical therapy. Cardiac resynchronization therapy (CRT) has become an established treatment for patients with symptomatic HFrEF and electrical dyssynchrony. Conventional biventricular pacing improves ventricular synchrony and clinical outcomes; however, approximately one-third of treated patients do not achieve a satisfactory response.

Conduction system pacing (CSP), particularly left bundle branch area pacing (LBBAP), has emerged as a physiological pacing strategy capable of directly engaging the native His-Purkinje conduction system. Compared with conventional biventricular pacing, CSP may produce more physiological ventricular activation, narrower paced QRS complexes, improved electrical synchrony, and greater reverse ventricular remodeling. Nevertheless, evidence regarding its long-term effectiveness in routine clinical practice remains limited, particularly in heterogeneous populations with different conduction abnormalities.

Study Rationale

The RESYNC-PACE study was designed to evaluate the effectiveness of individualized physiologic cardiac resynchronization strategies in a real-world population of patients with HFrEF requiring CRT.

The study investigates two complementary physiologic CRT approaches according to the underlying conduction disturbance. In patients with typical left bundle branch block (LBBB), left ventricular lead implantation is guided by the qLV ratio to achieve optimal electrical resynchronization through individualized coronary sinus lead positioning. In patients with intraventricular conduction delay (IVCD), a conduction system pacing strategy is applied using left bundle branch area pacing. When conduction system pacing alone results in incomplete electrical correction, defined by a paced QRS duration greater than 130 ms, an additional coronary sinus left ventricular lead is implanted to establish Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT).

This individualized treatment algorithm reflects contemporary physiological concepts of ventricular resynchronization rather than a single implantation strategy and represents the principal scientific concept investigated in the study.

Scientific Objectives

The study aims to determine whether physiologic CRT strategies provide superior long-term clinical outcomes compared with conventional biventricular CRT when implemented in routine clinical practice.

In addition to evaluating clinical outcomes, the study investigates the relationship between electrical resynchronization, ventricular reverse remodeling, myocardial scar characteristics assessed by cardiac magnetic resonance imaging, and long-term prognosis. Particular emphasis is placed on identifying imaging-, electrocardiographic-, and device-derived predictors of CRT response that may facilitate patient selection and optimization of resynchronization therapy.

Study Methodology

RESYNC-PACE is a single-center, ambispective observational cohort study performed at the University of Pécs Clinical Centre Heart Institute. Consecutive patients undergoing physiologic CRT constitute the prospective cohort, while a historical cohort of patients treated with conventional biventricular CRT serves as the comparator.

All therapeutic procedures are performed as part of routine clinical care using commercially available CE-marked cardiac implantable electronic devices according to their approved indications and current international guideline recommendations. The study does not introduce experimental devices or procedures beyond standard clinical practice but prospectively evaluates the clinical performance of an individualized physiological CRT algorithm.

The comprehensive study database integrates demographic, clinical, electrocardiographic, echocardiographic, cardiac magnetic resonance imaging, procedural, device-derived, and long-term follow-up data. This integrated approach enables detailed evaluation of the mechanisms underlying CRT response and supports the development of patient-specific resynchronization strategies.

Expected Clinical Significance

The RESYNC-PACE study is expected to generate real-world evidence regarding the effectiveness of conduction system pacing-guided CRT strategies and individualized resynchronization algorithms. The findings may improve patient selection, optimize implantation strategies for different conduction disorders, and contribute to the growing evidence supporting physiologic cardiac resynchronization therapy in patients with heart failure.

Typ studie

Pozorovací

Zápis (Odhadovaný)

50

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Peter Ezer MD PhD, assistant professor
  • Telefonní číslo: +36305468840
  • E-mail: ezerpeti@gmail.com

Studijní místa

    • Baranya
      • Pécs, Baranya, Maďarsko, 7621
        • Heart Institute , University of Pécs

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The study population consists of adult patients with heart failure with reduced ejection fraction (HFrEF) who are treated at the University of Pécs Clinical Centre Heart Institute and meet contemporary guideline indications for cardiac resynchronization therapy (CRT). Eligible participants have symptomatic heart failure despite guideline-directed medical therapy, left ventricular systolic dysfunction, and evidence of electrical dyssynchrony manifested by left bundle branch block (LBBB) or intraventricular conduction delay (IVCD). The prospective cohort includes patients undergoing conduction system pacing-based CRT as part of routine clinical care, while the historical control cohort includes patients previously treated with conventional biventricular CRT at the same institution. The study population represents a real-world heart failure population routinely referred for CRT implantation in tertiary cardiovascular care.

Popis

Inclusion Criteria:

  • Age ≥18 years.
  • Symptomatic heart failure despite guideline-directed medical therapy.
  • Left ventricular ejection fraction (LVEF) ≤40%.
  • Indication for cardiac resynchronization therapy according to contemporary ESC guideline recommendations.
  • QRS duration ≥150 ms with either:

Left bundle branch block (LBBB), or Intraventricular conduction delay (IVCD).

  • Planned implantation of a CRT system
  • Ability to provide written informed consent
  • Expected survival greater than 24 months.

Exclusion Criteria:

  • Age <18 years and Age 100 < years
  • Pregnancy or breastfeeding.
  • Inability or unwillingness to provide informed consent.
  • Life expectancy <12 months due to non-cardiac comorbidities.
  • Active systemic infection or infection involving a cardiac implantable electronic device.
  • Reversible causes of heart failure expected to improve without CRT.
  • Participation in another interventional clinical trial that may affect study outcomes.
  • Inability to comply with follow-up requirements.
  • Missing essential baseline or follow-up data (retrospective cohort).
  • Any condition that, in the opinion of the investigators, would make participation inappropriate or interfere with study assessments.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Left bundle branch block patients

LBBB Cohort (qLV-guided Cardiac Resynchronization Therapy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and complete left bundle branch block (LBBB) according to contemporary guideline criteria. Cardiac resynchronization therapy is performed using a personalized implantation strategy guided by the qLV ratio, defined as the interval between QRS onset and local left ventricular activation divided by the intrinsic QRS duration. The left ventricular lead is positioned at the site with the longest achievable electrical delay to maximize resynchronization benefit. Patients receive either conventional biventricular CRT or LOT- CRT according to clinical decision-making and anatomical feasibility. The cohort is followed longitudinally to evaluate the relationship between qLV-guided lead placement, electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
Ostatní jména:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.
Intraventricular conduction delay patients

IVCD Cohort (Conduction System Pacing-Guided Resynchronization Strategy)

Patients in this cohort have symptomatic heart failure with reduced left ventricular ejection fraction and intraventricular conduction delay (IVCD) without typical left bundle branch block morphology. The resynchronization strategy is guided by the degree of electrical correction achieved with conduction system pacing. During implantation, left bundle branch area pacing (LBBAP) is attempted and paced QRS duration is assessed. If conduction system pacing alone results in a paced QRS duration greater than 130 ms, a Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT) system is implanted by adding a left ventricular lead to further improve ventricular synchrony. The cohort is followed longitudinally to evaluate the association between electrical resynchronization, reverse ventricular remodeling, heart failure hospitalization, and all-cause mortality.

Conduction System Pacing-Guided Cardiac Resynchronization Therapy is an individualized resynchronization strategy used in patients with heart failure, reduced left ventricular ejection fraction, and electrical dyssynchrony. The intervention is based on direct recruitment of the native cardiac conduction system through left bundle branch area pacing (LBBAP). During implantation, electrical resynchronization is assessed using electrocardiographic and device-derived parameters. In patients with intraventricular conduction delay or incomplete electrical correction, additional left ventricular pacing may be provided using a coronary sinus lead, resulting in Left Bundle Branch Area Pacing Optimized Cardiac Resynchronization Therapy (LOT-CRT). The intervention aims to achieve more physiological ventricular activation than conventional biventricular pacing, improve electrical synchrony, promote reverse ventricular remodeling, and reduce heart failure-related adverse events.
Ostatní jména:
  • Cardiac resynchronization therapy using left bundle branch area pacing with or without LV lead optimization.
  • Cardiac resynchronization guided by conduction system pacing to improve ventricular synchrony.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Composite of All-Cause Mortality and Heart Failure Hospitalization
Časové okno: 24 months
Time to first occurrence of the composite endpoint of all-cause mortality or hospitalization due to worsening heart failure during the 24-month follow-up period.
24 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Left Ventricular Ejection Fraction (LVEF)
Časové okno: Baseline to 24 months

Change in left ventricular ejection fraction measured by transthoracic echocardiography between baseline and 24-month follow-up.

Ejection fraction is measured in percentage (%). Improvement in ejection fraction is detected as increase in percentage-value.

Baseline to 24 months
Change in Left Ventricular End-Systolic Volume ( LV ESV)
Časové okno: Baseline to 24 months

Change in left ventricular end-systolic volumen measured by echocardiography between baseline and 24-month follow-up.

Left ventricular end-systolic volume in measured in mililiters ( ml) , decrease in LV ESV is a sign of clinical response on therapy.

Baseline to 24 months
Change in paced QRS Duration
Časové okno: Baseline to 24 months

Reduction in QRS duration following cardiac resynchronization therapy compared with baseline electrocardiographic measurements.

Paced QRS duration is measured in miliseconds (ms). Decrease in paced QRS duration compared to preoperative QRS duration is marked as a good signal in cardiac resynchronization therapy.

Baseline to 24 months
New York Heart Association Heart Failure Functional Status
Časové okno: Baseline to 24 months

Change in New York Heart Association (NYHA) functional class from baseline to follow-up. Stage I-IV.

NYHA improvement is detected as decrease in NYHA stage grade.

Baseline to 24 months

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Device-Related and Procedure-Related Complications
Časové okno: 24 months
Incidence of device-related and procedure-related adverse events, including lead dislodgement, infection, pneumothorax, pocket hematoma, and system revision.
24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

29. června 2026

Primární dokončení (Odhadovaný)

29. června 2030

Dokončení studie (Odhadovaný)

29. června 2031

Termíny zápisu do studia

První předloženo

28. června 2026

První předloženo, které splnilo kritéria kontroly kvality

28. června 2026

První zveřejněno (Aktuální)

6. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

8. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • FF107 RESYNC-PACE ver1.0
  • Biotronik Research Grant FF107 (Jiné číslo grantu/financování: BIOTRONIK SE & Co. KG Woermannkehre 1 12359 Berlin)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

ndividual participant data will be shared only in a de-identified form and in accordance with applicable data protection regulations, institutional policies, and informed consent provisions. Data sharing may be limited where participant privacy, ethical considerations, or legal requirements prevent full disclosure of individual-level data.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .